SCHEMBL21189312

SCHEMBL21189312

Cc1cc(NC(=O)c2ccc(F)c3c2OCC[C@@H]3NC(=O)OC[C@@H]2CCC(=O)N2C)ccc1F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
CHRM3 P20309 4/20 0.33
TRPV1 Q8NER1 3/20 0.33
POLB P06746 1/20 0.33
HTR2B P41595 1/20 0.32
GRM4 Q14833 3/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CASP6 P55212 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189314 1.00 DRD4 (0.33) DRD4TMEM97SIGMAR1IRAK4CHRM3
SCHEMBL21189300 0.84 SMN1; SMN2 (0.38) DRD4TMEM97SIGMAR1POLBHCRTR1
SCHEMBL21189295 0.84 IRAK4 (0.35) DRD4TMEM97SIGMAR1IRAK4HTR2B
SCHEMBL21189298 0.84 IRAK4 (0.35) DRD4TMEM97SIGMAR1IRAK4HTR2B
SCHEMBL21189301 0.84 GRM4 (0.34) DRD4TMEM97SIGMAR1TRPV1HTR2B
SCHEMBL21189307 0.83 HDAC3 (0.38) DRD4TMEM97SIGMAR1CHRM3HTR2B
SCHEMBL21189248 0.83 APOB (0.40) DRD4TMEM97SIGMAR1HTR2BHCRTR1
SCHEMBL21189433 0.83 APOB (0.40) DRD4TMEM97SIGMAR1HTR2BHCRTR1
SCHEMBL21189362 0.83 IRAK4 (0.35) DRD4TMEM97SIGMAR1IRAK4HTR2B
SCHEMBL21189302 0.80 NPC1 (0.36) DRD4TMEM97SIGMAR1HTR2BGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS DRD4 4324/4885TMEM97 4242/4885SIGMAR1 3876/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS DRD4 4324/4885TMEM97 4242/4885SIGMAR1 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.